Lotus Pharmaceutical Co., Ltd.

TWSE:1795 Stock Report

Market Cap: NT$75.7b

Lotus Pharmaceutical Management

Management criteria checks 1/4

Lotus Pharmaceutical's CEO is Petar Vazharov, appointed in Jan 2018, has a tenure of 6.83 years. directly owns 0.38% of the company’s shares, worth NT$285.50M. The average tenure of the management team and the board of directors is 3.3 years and 1.4 years respectively.

Key information

Petar Vazharov

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure6.8yrs
CEO ownership0.4%
Management average tenure3.3yrs
Board average tenure1.4yrs

Recent management updates

Recent updates

Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Nov 16
Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Lotus Pharmaceutical's (TWSE:1795) Earnings Are Weaker Than They Seem

Nov 14
Lotus Pharmaceutical's (TWSE:1795) Earnings Are Weaker Than They Seem

Here's Why Lotus Pharmaceutical (TWSE:1795) Has A Meaningful Debt Burden

Oct 23
Here's Why Lotus Pharmaceutical (TWSE:1795) Has A Meaningful Debt Burden

Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Aug 14
Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)

Jul 18
Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)

Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Apr 24
Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Apr 09
Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

Mar 22
Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Apr 04
These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Mar 09
Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Feb 11
Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Jan 21
Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

Dec 31
Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Dec 10
I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

Nov 19
Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

CEO Compensation Analysis

How has Petar Vazharov's remuneration changed compared to Lotus Pharmaceutical's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

NT$4b

Jun 30 2024n/an/a

NT$4b

Mar 31 2024n/an/a

NT$4b

Dec 31 2023n/an/a

NT$4b

Sep 30 2023n/an/a

NT$4b

Jun 30 2023n/an/a

NT$5b

Mar 31 2023n/an/a

NT$4b

Dec 31 2022n/an/a

NT$3b

Sep 30 2022n/an/a

NT$3b

Jun 30 2022n/an/a

NT$1b

Mar 31 2022n/an/a

NT$1b

Dec 31 2021NT$35mNT$28m

NT$1b

Sep 30 2021n/an/a

NT$1b

Jun 30 2021n/an/a

NT$1b

Mar 31 2021n/an/a

NT$1b

Dec 31 2020NT$18mNT$14m

NT$1b

Sep 30 2020n/an/a

NT$848m

Jun 30 2020n/an/a

NT$769m

Mar 31 2020n/an/a

NT$519m

Dec 31 2019NT$13mNT$7m

NT$663m

Compensation vs Market: Insufficient data to establish whether Petar's total compensation is reasonable compared to companies of similar size in the TW market.

Compensation vs Earnings: Petar's compensation has increased by more than 20% in the past year.


CEO

Petar Vazharov

6.8yrs

Tenure

NT$34,721,000

Compensation

Mr. Petar Antonov Vazharov serves as a Director at Alvogen Korea Co. Ltd. Since March 31, 2021. He is an Executive Vice President of the Asia Pacific Region of Alvogen Group.He is General Manager of Alvog...


Leadership Team

NamePositionTenureCompensationOwnership
Petar Vazharov
CEO & Director6.8yrsNT$34.72m0.38%
NT$ 285.5m
Eeling Chan
Chief Financial Officer8yrsNT$5.19m0.010%
NT$ 7.6m
Vamsi Kosaraju
Chief Operations Officerno datano datano data
Gwen Hsieh
Chief Information Officer3.3yrsno data0.0084%
NT$ 6.4m
Yu-Ying Yang
Associate Director of Co-Operate Communicationno datano datano data
Boon Tan
Deputy General Managerno datano data0.0077%
NT$ 5.9m
Edin Buljubasic
Vice Presidentno datano data0.057%
NT$ 42.8m
Yingming Yue
Vice Presidentno datano data0.011%
NT$ 8.6m
Valerie Lau
Chief Commercial Officer-APACless than a yearno datano data
Manish Chawla
Vice President of Research and Developmentno datano data0.026%
NT$ 20.0m

3.3yrs

Average Tenure

Experienced Management: 1795's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Petar Vazharov
CEO & Director10.2yrsNT$34.72m0.38%
NT$ 285.5m
Vilhelm Wessman
Chairman9.6yrsNT$959.00kno data
Karl Alexius Tiger Karlsson
Independent Director1.4yrsno datano data
Oranee Tangphao-Daniels
Director2.4yrsno datano data
Arni Hardarson
Representative Directorless than a yearNT$959.00kno data
Yves Hermes
Director2.4yrsno datano data
Chuan-Fen Wang
Independent Dierctor1.4yrsno datano data
Nat Ativitavas
Representative Director1.2yrsno datano data
Krisana Winitthumkul
Director2yrsno datano data
Ivy Yang
Independent Directorless than a yearno datano data
Thariswan Tiensawat
Representative Directorless than a yearno datano data

1.4yrs

Average Tenure

55yo

Average Age

Experienced Board: 1795's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.